Dementia and Alzheimer Disease

Those with ≥150 min per week in moderated or vigorous activities were low risk while those with less than 150 or sedentary activity were higher risk.

The tau tracer can support a pathological diagnosis of Alzheimer disease by identifying the underlying presence of NFTs at the B3 level.

The new technology has applications for diagnosis and recruitment for disease-modifying trials.

Despite patients being off treatment for an average of 23 months, patients treated with Eisai’s BAN2401 remained amyloid PET negative in an open-label extension preliminary analysis.

Flortaucipir PET tracer’s can identify high levels of neuropathologic changes and neurofibrillary tangles.

Since 2005, opioid use has increased amongst older dementia patients.

Better testing for SDB and other sleep disorders are needed for the older population.

Investigators in a new study find little difference between cognitive screenings and standard care in limiting emergency department visits from nursing home residents.

The task force’s recommendations will remain unchanged since the last version in 2014.

The Prometra II offers a pressure-driven, valve-gated delivery mechanism that allows for novel programming modes of intermittent flow followed by periods of no flow—a feature unique to this device.

Physically active geriatric adults are generally healthier physically and mentally than inactive older adults.

Data from an analysis of the Rush Memory and Aging Project found consumption of flavonols was tied to a decreased risk of developing Alzheimer dementia.

A meta-analysis shows an association between respiratory burden and greater dementia risk, but the causes are still unknown.

Quetiapine, an antipsychotic known to treat mood disorders, is linked to increasing the risk of traumatic brain injuries for patients suffering from Alzheimer disease.

New research emphasizes importance of sleep in decreasing the odds of developing Alzheimer disease.

In a new study, a team of investigators use new imaging techniques to accurately predict brain tissue damage for patients with Alzheimer disease.

Early diagnosis of dementia could lead to earlier treatment.

Investigators decipher the differences along racial lines for cerebrospinal fluid amyloid, tau biomarkers and associated cutoffs for patients with mild cognitive impairment.

Without an FDA approved drug in the last decade, investigators have found ways to improve diagnostics for patients suffering from Alzheimer disease.

Arjun Masurkar, MD, PhD, discusses some of the issues with Alzheimer disease clinical trials.

Arjun Masurkar, MD, PhD, discusses how genetic testing could usher in a new wave of diagnostics for Alzheimer disease.

Arjun Masurkar, MD, PhD, previews some of the new medications that could help treat Alzheimer disease, while reviewing some of the advancements of the last decade.

During Kidney Week, Christine Liu, MD, discusses some of the issues geriatric patients face.